In line Q1 and on track deleveraging; worth a go
15/05/24 -"The Q1 results largely met the consensus, as the firm’s key blood-plasma-derived proteins witnessed strong demand, profitability continued to expand yoy and the deleveraging initiatives remained on ..."
Pages
53
Language
English
Published on
15/05/24
You may also be interested by these reports :
17/09/25
The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum